OakChart

OS Therapies Inc

OSTXHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 10:10 AM ET

0.8921+0.0021 (0.24%)
2026-11-11 16:11 CET
Market cap
46.57 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-39.37 USD m
Free cash flow, TTM
-18.53 USD m
EPS diluted, TTM
-1.04
P/E
-
Compare

Price

OSTX against its 20, 50 and 200-day averages
2050200miss
0.501.001.502.003.0M6.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OSTXclose 0.8920-day 1.1750-day 1.47200-day 1.550.89

60.4% under 2.25 on 29 Jun 2026. Last 15 sessions, 129.3% high to low

Profile

OSTX
52-week range, 19% of the way up
0.582.25

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Grasonville, MD.

Employees5
IPOAug 01, 2024
Beta-0.30
ATR, 14d0.13
Rel volume0.42
Short float5.65%
Insider own6.55%
Inst own5.73%

Snapshot

6 groups

Valuation

Index-
Market Cap46.68M
Enterprise Value47.54M
Income-39.37M
Sales0.00M
Book/sh-0.26
Cash/sh0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOAug 01, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C222.29
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.18
Current Ratio0.18
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.04
EPS next Y-0.19
EPS next Q-0.14
EPS this Y24.74%
EPS next Y74.24%
EPS next 5Y-
EPS past 3/5Y-47.63% 67.91%
Sales past 3/5Y- -
EPS Y/Y TTM-41.63%
Sales Y/Y TTM-
EPS Q/Q-8.86%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-12.36% -

Ownership

Insider Own6.55%
Insider Trans0.00%
Inst Own5.73%
Inst Trans0.47%
ROA-389.65%
ROE-914.04%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-23.76%
SMA50-39.46%
SMA200-42.28%
Trades-

Technical

Shs Outstand52.32M
Shs Float48.89M
Short Float5.65%
Short Ratio4.11
Short Interest2.76M
52W High2.25 -60.35%
52W Low0.58 53.84%
Volatility27.40% 12.04%
ATR (14)0.13
RSI (14)20.87
Beta-0.30
Rel Volume0.42
Avg Volume671.52K
Volume41,719

Performance

Perf Week-22.43%
Perf Month-38.48%
Perf Quarter-44.24%
Perf Half Y-50.16%
Perf YTD-36.28%
Perf Year-52.80%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price8.25
Prev Close0.89
Price0.89
Change %0.24%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 09, 2026InitiatedRRoth CapitalBuy$7+684.7%
Apr 02, 2025InitiatedLLake StreetBuy$19+2,029.8%

Peers

Mkt cap
TickerCompanyMkt cap
GLSIGreenwich LifeSciences Inc242.34M
ANIXAnixa Biosciences Inc106.55M
ELTXElicio Therapeutics Inc45.57M
PDSBPDS Biotechnology Corp106.58M
ONCYOncolytics Biotech Inc49.41M
BCTXBriaCell Therapeutics Corp31.43M
SLSSELLAS Life Sciences Group Inc1.70B
HURATuHURA Biosciences Inc100.05M
MAIAMAIA Biotechnology Inc65.46M
IMNNImunon Inc4.49M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 206
  • OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
  • OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial (Newsfile Corp.) -14.77%
  • OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million (Newsfile Corp.)
  • OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma (Newsfile)
  • OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial (Newsfile) -6.88%
  • Loading…
  • OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer (Newsfile Corp.)
  • OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) (Newsfile Corp.)
  • OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis (Newsfile Corp.)
  • OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program (Newsfile Corp.)
  • OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing (Newsfile Corp.)
  • OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial (Newsfile Corp.)
  • OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance (Newsfile Corp.)
  • OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates (Newsfile Corp.) -9.26%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.200-0.178-0.2000.000.005
2026Q12026-05-18-0.270-0.174-0.2700.000.975
2025Q42026-03-31-0.360-0.136-0.3630.000.005
2025Q32025-11-17-0.210-0.123-0.2150.000.004
2025Q22025-08-14-0.188-0.115-0.1810.000.004
2025Q12025-05-16-0.180-0.086-0.1820.000.003
2024Q42025-03-31-0.190-0.143-0.2380.000.003
2024Q32024-11-15-0.180-0.120-0.1360.000.302
2024Q22024-08-28-0.960-0.260-0.0740.28-1
2026Q3---0.138--0.004
2026Q4---0.158--0.004
2027Q1---0.060--4.372
2027Q2---0.060--4.562
2027Q3---0.050--4.941
2027Q4---0.070--14.782
2028Q1---0.047--3.721

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-0.880-1.067-0.5220.000.21
2025FY-0.980-0.690-0.9800.000.00
2026FY--0.738--0.00
2027FY--0.190--26.57
2028FY-0.060--168.63
2029FY-0.905--211.1
2030FY-0.985--216.56

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-161000.000.000.00
2026Q3S2026-08-192000.000.000.00
2026Q3S2026-08-173001.000.003.00
2026Q3S2026-08-143001.000.003.00
2026Q3S2026-07-083001.000.003.00
2026Q3S2026-05-212001.500.003.00
2026Q3S2026-05-183004.680.0011.04
2026Q3S2026-05-112007.023.0011.04
2026Q3S2026-03-3110011.0411.0411.04
2026Q3S2025-11-172007.023.0011.04
2026Q3S2025-11-112007.023.0011.04
2026Q3S2025-11-102007.023.0011.04
2026Q3S2025-11-092007.023.0011.04
2026Q3S2025-11-082007.023.0011.04

Estimate history

EPS, annual-288.62-326.499-0.306-0.374-0.522-0.983-1.0434
Period202020212022202320242025TTM
EPS, quarterly-0.074-0.136-0.238-0.182-0.181-0.215-0.363-0.269-0.197
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual20.88520.88520.88521.18120.8737.11345.283
Period202020212022202320242025MRQ
Shares, quarterly21.18121.18120.8721.34729.66533.2737.11339.27845.283
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.500.360.000.000.000.810.07
Gross Profit-0.50-0.36-0.00-0.00-0.00-0.81-0.07
Selling, General and Administrative Excl. Other37.1128.346.814.344.443,404.431,397.13
Research and Development25.4816.002.843.213.292,173.37601.71
Other Operating Expense0.000.000.000.000.001,159.644,250.00
Operating Income-37.61-28.71-6.81-4.34-4.45-4,564.87-5,647.20
Interest Expense0.080.002.053.451.812,160.18461.79
Unusual Expense0.00-1.420.000.000.000.000.00
Net Income Before Taxes-39.37-28.75-8.88-7.79-6.25-6,725.05-6,027.70
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-39.37-28.75-8.88-7.79-6.25-6,725.05-6,027.70
Net Income From Continuing Operations-39.37-28.75-8.88-7.79-6.25-6,725.05-6,027.70
Net Income-39.37-28.75-10.89-7.92-6.38-6,818.80-6,027.70
EPS (Recurring)-0.90-1.02-0.52-0.37-0.31-326.50-288.62
EPS (Basic, Before Extraordinaries)-1.04-0.98-0.52-0.37-0.31-326.50-288.62
EPS (Diluted)-1.04-0.98-0.52-0.37-0.31-326.50-288.62
EBITDA-37.11-28.34-6.81-4.34-4.45-4,564.07-5,647.13
Non-Operating Income (Expense)-1.68-1.47-0.022E-060.000.0081.28
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense5.194.270.27----
Shares Outstanding45.2837.1120.8721.1820.8820.8820.88
Market Capitalization46.5746.5790.9099.82---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.120.120.110.000.000.00
Gross Profit-0.12-0.12-0.12-0.12-0.11-0.00-0.000.00
Selling, General and Administrative Excl. Other8.4510.0411.866.754.735.002.972.44
Research and Development5.957.238.673.632.391.310.871.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.58-10.17-11.99-6.88-4.84-5.00-2.97-2.44
Interest Expense0.010.080.000.000.000.000.010.44
Unusual Expense0.000.000.000.00-0.30-1.120.000.00
Net Income Before Taxes-8.63-10.40-13.46-6.88-4.54-3.88-2.99-2.88
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.63-10.40-13.46-6.88-4.54-3.88-2.99-2.88
Net Income From Continuing Operations-8.63-10.40-13.46-6.88-4.54-3.88-2.99-2.88
Net Income-8.63-10.40-13.46-6.88-4.54-3.88-4.96-2.88
EPS (Recurring)-0.20-0.27-0.36-0.22-0.19-0.22-0.24-0.14
EPS (Basic, Before Extraordinaries)-0.20-0.27-0.36-0.22-0.18-0.18-0.24-0.14
EPS (Diluted)-0.20-0.27-0.36-0.22-0.18-0.18-0.24-0.14
EBITDA-8.45-10.04-11.86-6.75-4.73-5.00-2.97-2.44
Non-Operating Income (Expense)-0.05-0.15-1.470.000.000.00-0.020.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.331.441.600.810.910.94--
Shares Outstanding45.2839.2837.1133.2729.6621.3520.8721.18
Market Capitalization46.5749.6549.3062.0252.8233.5290.9056.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments0.275.530.040.1780.791,232.78
Short Term Receivables0.000.000.000.00229.93430.49
Inventories0.000.000.000.000.000.00
Other Current Assets0.060.000.000.000.9612.80
Total Current Assets0.335.530.040.17311.671,676.06
Net Property, Plant & Equipment0.000.010.010.0113.081.95
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets6.500.000.000.000.000.00
Other Assets0.000.000.750.320.000.00
Total Assets6.845.540.800.51324.751,678.01
Short Term Debt Incl. Current Port. of LT Debt0.000.0014.613.041,612.05871.25
Accounts Payable9.941.662.721.23856.520.04
Other Current Liabilities1.832.977.391.881,062.181,231.84
Total Current Liabilities11.764.6324.716.153,530.762,103.13
Long Term Debt0.000.000.0010.357,339.615,901.70
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.001.470.000.00
Total Liabilities11.764.6324.7117.9710,870.368,004.83
Non-Equity Reserves0.100.100.100.10100.000.00
Preferred Stock - Carrying Value1.076.050.000.001.300.00
Common Equity-6.10-5.24-24.02-17.56-10,646.92-6,326.82
Total Shareholders Equity-5.020.81-24.02-17.56-10,645.62-6,326.82
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-5.020.81-24.02-17.56-10,645.62-6,326.82
Total Liabilities & Stockholders Equity6.845.540.800.51324.741,678.01
Book Value Per Share-0.16-0.25-1.13-0.84-509.80-302.94
Tangible Book Value Per Share-0.34-0.25-1.13-0.84-509.80-302.94
Full-Time Employees554433
Price to Book Ratio-3.38-128.18-140.76---
Return on Assets-464.58-280.36-1,192.11-3.85-671.58-
Return on Invested Capital--1,094.65----
Quick Ratio0.031.200.000.030.090.80
Current Ratio0.031.200.000.030.090.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-39.37-28.75-8.88-7.79-6.25-6,725.05-6,027.70
Depreciation0.500.360.000.000.000.810.07
Other Funds (Non Cash)6.875.041.732.761.511,728.362,650.11
Funds from Operations-32.00-23.35-7.15-5.02-4.74-4,995.88-3,377.52
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital13.479.11-0.132.020.95593.07964.39
Cash from Operating Activities-18.53-14.24-7.28-3.01-3.79-4,402.81-2,413.13
Capital Expenditures0.00-0.470.000.000.00-11.93-2.01
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.050.00-289.70
Other Sources0.000.000.000.000.28212.41450.00
Cash from Investing Activities0.00-0.470.000.000.23200.47158.29
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock14.109.4411.280.000.000.002.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock14.109.4411.280.000.000.002.10
Proceedsfrom Stock Options5.909.4411.280.000.000.002.10
Issuance or Reduction of Debt, Net1.830.001.503.163.822,950.353,475.58
Change in Long Term Debt0.000.000.000.003.822,950.353,475.58
Issuance of Long Term Debt0.000.000.000.003.822,950.353,595.58
Reduction of Long Term Debt0.000.000.000.000.000.00-120.00
Net Financing Active Other Cash Flow0.000.000.00-0.28-0.17100.000.00
Other Financing Activities Uses0.000.000.00-0.28-0.170.000.00
Cash from Financing Activities15.949.4412.782.873.653,050.353,477.68
Net Change in Cash-2.60-5.265.49-0.130.09-1,151.991,222.84
Free Cash Flow-18.53-14.24-7.28-3.01-3.79-4,414.74-2,415.14
Preferred Dividends (Cash Flow)-0.00----0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.210.920.271.882.802.97
Short Term Receivables3.100.000.000.040.000.02
Inventories0.000.000.000.000.000.00
Other Current Assets0.340.000.060.400.751.10
Total Current Assets3.640.920.332.323.554.10
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets6.266.386.506.636.750.15
Other Assets0.000.000.000.000.000.00
Total Assets9.907.306.848.9510.314.25
Short Term Debt Incl. Current Port. of LT Debt0.001.340.000.000.000.00
Accounts Payable18.8713.859.943.372.701.62
Other Current Liabilities1.771.761.830.770.761.92
Total Current Liabilities20.6416.9511.764.153.463.54
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities20.6416.9511.764.153.463.54
Non-Equity Reserves0.100.100.100.100.100.10
Preferred Stock - Carrying Value1.071.071.071.071.814.80
Common Equity-11.91-10.82-6.103.644.94-4.19
Total Shareholders Equity-10.84-9.75-5.024.716.750.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-10.84-9.75-5.024.716.750.61
Total Liabilities & Stockholders Equity9.907.306.848.9510.314.25
Book Value Per Share-0.26-0.28-0.160.110.17-0.20
Tangible Book Value Per Share-0.40-0.44-0.34-0.09-0.06-0.20
Full-Time Employees--5---
Price to Book Ratio-3.38-5.1212.8111.76-9.59-6.14
Return on Assets-389.65-610.85-464.58-334.55-245.09-426.54
Return on Equity----914.04--
Return on Invested Capital----146.13-67.18-631.75
Quick Ratio0.180.050.030.561.031.16
Current Ratio0.180.050.030.561.031.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-8.63-10.40-13.46-6.88-4.54-3.88
Depreciation0.120.120.120.120.110.00
Other Funds (Non Cash)1.381.792.641.050.610.73
Funds from Operations-7.13-8.48-10.69-5.70-3.81-3.14
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.603.916.960.991.45-0.30
Cash from Operating Activities-5.53-4.56-3.73-4.71-2.36-3.44
Capital Expenditures0.000.000.000.00-0.32-0.15
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.02-0.02
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.29-0.17
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.823.382.123.782.481.05
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.823.382.123.782.481.05
Proceedsfrom Stock Options0.000.002.123.782.481.05
Issuance or Reduction of Debt, Net0.001.830.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.825.212.123.782.481.05
Net Change in Cash-0.710.65-1.61-0.93-0.17-2.56
Free Cash Flow-5.53-4.56-3.73-4.71-2.36-3.44

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.65%2.8M48.9M585.26K
2026-10-156.45%2.8M43.7M579.62K
2026-09-305.93%2.6M43.7M581.84K
2026-09-154.83%2.1M43.7M616.41K
2026-08-316.36%2.8M43.4M586.02K
2026-08-146.00%2.6M43.1M652.81K
2026-07-316.53%2.8M42.5M698.20K
2026-07-157.69%2.6M34.3M820.76K
2026-06-306.57%2.3M34.3M768.41K
2026-06-155.93%2.0M34.3M690.11K
2026-05-294.93%1.7M33.7M696.36K
2026-05-153.91%1.3M33.7M617.49K
2026-04-304.65%1.4M29.8M628.62K
2026-04-154.68%1.4M29.8M540.53K
2026-03-314.59%1.4M29.8M575.98K
2026-03-135.19%1.3M24.9M573.64K
2026-02-276.22%1.6M24.9M537.33K
2026-02-135.50%1.4M24.9M538.70K
2026-01-303.87%1.0M24.9M471.44K
2026-01-153.39%0.8M24.9M450.73K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-23DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-198-KCurrent report2026-10-15SEC
2026-10-053Initial statement of beneficial ownership of securities2026-09-29SEC
2026-10-053Initial statement of beneficial ownership of securities2026-09-29SEC
2026-10-058-KCurrent report2026-09-29SEC
2026-09-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-108-KCurrent report2026-09-10SEC
2026-09-10424B7SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-25DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-218-KCurrent report2026-08-21SEC
2026-08-21424B5SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-06SEC
2026-08-068-KCurrent report2026-07-31SEC
2026-08-06424B5SEC
2026-07-298-KCurrent report2026-07-23SEC
2026-07-24ARSAnnual report to security holders. 2025-12-31SEC
2026-07-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.75%
CM Management, LLC0.90%
GEODE CAPITAL MANAGEMENT, LLC0.79%
BlackRock, Inc.0.54%
HOWARD FINANCIAL SERVICES, LTD.0.53%
VANGUARD FIDUCIARY TRUST CO0.39%
STATE STREET CORP0.27%
MARSHALL WACE, LLP0.23%
HighTower Advisors, LLC0.20%
NORTHERN TRUST CORP0.16%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.93%
VANGUARD EXTENDED MARKET INDEX FUND0.81%
Fidelity Extended Market Index Fund0.37%
iShares Micro-Cap ETF0.25%
Fidelity Series Total Market Index Fund0.11%
Ultra-Small Company Market Fund0.10%
Fidelity Total Market Index Fund0.09%
1290 VT Micro Cap Portfolio0.02%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. OSTX. Cached 15 minutes.

Some panels did not load: insider.